查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1990132

導管相關血流感染疾病市場：按產品類型、塗層和最終用戶分類 - 2026-2032年全球市場預測

Catheter-related Bloodstream Infections Market by Product Type, Coating, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，導管相關血流感染疾病市場價值將達到 18.4 億美元，到 2026 年將成長至 19.4 億美元，到 2032 年將達到 27.9 億美元，複合年成長率為 6.08%。

主要市場統計數據
基準年 2025 18.4億美元
預計年份：2026年 19.4億美元
預測年份 2032 27.9億美元
複合年成長率 (%) 6.08%

一個專注於臨床要求、相關人員責任以及影響導管相關感染疾病預防和醫療設備引入的匯聚因素的框架。

導管相關血流感染在急診和社區醫療機構中仍然是一個持續存在的挑戰，它不僅造成了沉重的臨床負擔，也推動著醫療設備設計、臨床實踐和感染預防策略的不斷創新。本文從病人安全需求、不斷發展的醫療標準以及臨床結果與採購和監管決策的交匯點來探討這個問題。透過圍繞技術、實踐和政策展開討論，相關人員將能夠更有效地評估哪些干預措施能夠帶來最大的臨床和營運價值。

醫療設備科學創新、實證通訊協定和跨部門合作如何匯聚一堂，重新定義感染預防策略和臨床部署途徑。

醫療系統、臨床醫生和製造商應對導管相關血流感染的方式正經歷著重大變革。材料科學和表面工程的進步正在為器械層面帶來新的防護能力，而插入技術、維護通訊協定和即時監測的逐步改進則正在改變臨床工作流程。這些變革共同建構了一個更加多層次的感染控制系統，其範圍不再局限於單一產品或操作，而是涵蓋了整個醫療照護體系。

本研究評估了關稅、採購、定價和供應商策略的變化如何影響感染預防產品的採購決策以及供應鏈的韌性。

美國近期關稅調整為導管相關感染預防產品的供應鏈計算和採購決策引入了新的變數。其累積影響不僅限於價格調整，還波及供應商的籌資策略、庫存管理以及國內製造商與國際供應商之間的競爭動態。採購團隊被迫重新評估供應商多元化、雙重採購和庫存緩衝策略，以降低下游短缺和成本波動的風險。

詳細的細分分析揭示了醫療設備類型、醫療環境和塗層技術如何相互交織，從而影響臨床選擇、採購和實施策略。

細分市場分析揭示了不同產品類型、終端用戶和塗層方法的趨勢差異，這些因素共同決定了產品的採用和創新重點。本研究基於產品類型，將中央靜脈導管和周邊靜脈導管區分開來。中央靜脈導管進一步分為非周邊置入中央靜脈導管和周邊置入中央靜脈導管，而周邊靜脈導管則包括中線導管和標準周邊靜脈導管。每個子類別都有其獨特的臨床適應症、留置時間方面的考慮以及影響器械選擇和相關預防策略的風險特徵。

關鍵地區法規結構、製造地和臨床實踐的多樣性如何推動設備部署和分銷策略的差異化？

區域趨勢影響臨床實踐、監管重點和供應鏈結構，並對在美洲、歐洲、中東和非洲以及亞太地區營運的相關人員產生重大影響。在美洲，政策優先考慮品質指標和報銷結果，迫使醫療機構優先考慮能夠顯著降低感染風險的干涉措施。同時，強大的國內生產能力為許多地區的供應鏈持續性提供了保障。相較之下，歐洲、中東和非洲（EMEA）地區的環境更為多元化，法規結構、醫療基礎設施成熟度和採購模式差異顯著，因此需要製定針對特定區域的策略並結合本地證據來支持產品推廣。

製造商和服務供應商之間採取競爭與合作並重的策略，優先考慮證據生成、整合解決方案和供應鏈彈性，以贏得臨床機構的信任。

醫療設備製造商、塗層技術供應商和服務機構之間的競爭正在影響產品開發和打入市場策略。主要企業正投資於新一代材料和塗層化學技術，以提高抗菌性能，同時最大限度地減少對合理使用抗菌藥物（AMS）舉措的影響。同時，隨著製造商致力於提供包含醫療設備、培訓和數位依從性工具的捆綁式解決方案，以改善臨床療效和客戶維繫，產品組合也呈現出明顯的多元化趨勢。

為製造商和醫療保健系統提供切實可行的、基於證據的舉措，以加速改善臨床結果、確保供應鏈連續性並安全地實施感染預防創新。

產業領導企業應採取切實可行的多面向策略來降低導管相關血流感染的發生率，平衡創新、推廣應用和系統層面的變革。應優先投資於臨床證據，以證明產品性能以及對感染率和資源利用的實際影響。除了醫療設備創新之外，還應進行前瞻性觀察研究，並與醫療系統合作，以深入了解治療效果和推廣應用。

採用透明的混合方法，結合臨床醫生訪談、指南審查和透過三角驗證進行檢驗整合，可以產生嚴謹且可操作的見解。

本分析的調查方法結合了第一手和第二手研究技術，以確保研究的嚴謹性、多方驗證以及與相關人員的相關性。第一手研究包括對醫療保健專業人員、感染控制專家、採購經理和行業高管進行結構化訪談，以收集關於醫療設備性能、部署障礙和營運重點的第一手觀點。除這些訪談外，還與監管專家和供應鏈經理進行了有針對性的討論，以了解監管影響和物流方面的考慮。

策略整合強調，將創新、證據和營運嚴謹性結合，對於持續降低感染風險和提高病患安全至關重要。

總之，應對導管相關血流感染需要一項綜合策略，該策略應將醫療設備創新、臨床實踐改進和價值鏈穩健性結合。導管設計和抗菌塗層的技術進步固然重要，但只有將其與嚴謹的證據收集、全面的培訓以及支持合規性的運作體系相結合，才能真正發揮其價值。在各相關人員努力應對關稅波動和區域差異之際，注重韌性、目標數據和協作實施將有助於區分有效和無效的項目。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：導管相關血流感染疾病市場：依產品類型分類

  • 中央靜脈導管
    • 非周邊置入中央靜脈導管
    • 周邊置入的中央靜脈導管
  • 周邊靜脈導管
    • 中線導管
    • 標準周邊靜脈導管

第9章：導管相關血流感染疾病市場（依塗層分類）

  • 抗菌塗層
    • 抗生素浸漬
    • 氯己定塗層
    • 銀塗層
  • 無塗層

第10章：導管相關血流感染疾病市場：依最終用戶分類

  • 門診手術中心
  • 居家照護設施
  • 醫院

第11章：導管相關血流感染疾病市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：導管相關血流感染疾病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：導管相關血流感染疾病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國導管相關血流感染疾病市場

第15章：中國導管相關血流感染疾病市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advacare Pharma
  • AstraZeneca PLC
  • Bactiguard AB
  • Becton, Dickinson and Company
  • CorMedix Inc
  • Fresenius Medical Care AG
  • Glenmark Pharmaceuticals Ltd.
  • IntegraDose Compounding Services, LLC
  • Johnson & Johnson Services, Inc
  • JoinHub Pharma
  • Lupin Ltd.
  • Lyka Hetero Healthcare Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • TauroPhar GmbH
  • Xellia Pharmaceuticals Ltd.
Product Code: MRR-5D693B46C67B

The Catheter-related Bloodstream Infections Market was valued at USD 1.84 billion in 2025 and is projected to grow to USD 1.94 billion in 2026, with a CAGR of 6.08%, reaching USD 2.79 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.84 billion
Estimated Year [2026] USD 1.94 billion
Forecast Year [2032] USD 2.79 billion
CAGR (%) 6.08%

A focused framing of clinical imperatives, stakeholder responsibilities, and the converging forces that shape catheter-related infection prevention and device adoption

Catheter-related bloodstream infections remain a persistent challenge across acute and community care environments, producing significant clinical burden and driving continuous innovation in device design, clinical practice, and infection prevention strategies. This introduction frames the issue in terms of patient safety imperatives, evolving standards of care, and the intersection of clinical outcomes with procurement and regulatory decision-making. By situating the discussion around technology, practice, and policy, stakeholders can more effectively assess where interventions will yield the greatest clinical and operational value.

Clinical teams face increasing pressure to reduce preventable infections as payers and regulators emphasize quality metrics and reimbursement-linked outcomes. At the same time, device manufacturers and hospital procurement leaders must balance clinical performance with cost containment and supply chain reliability. As a result, the landscape for catheter-related infection prevention is characterized by intensified collaboration between clinicians, infection preventionists, supply chain managers, and industry partners, fostering multidisciplinary solutions that integrate technology, training, and process optimization.

This introduction sets the stage for a detailed executive-level analysis by highlighting the key drivers that shape decision-making today: clinical efficacy of devices and coatings, procedural standards and bundles, workforce competency and adherence, and the broader economic and regulatory context that determines adoption pathways. By clarifying these themes up front, the subsequent sections can explore transformational shifts, segmentation dynamics, regional patterns, vendor strategies, and practical recommendations for leaders seeking to reduce infection risk while optimizing care delivery.

How innovations in device science, evidence-based protocols, and cross-sector collaboration are converging to redefine infection prevention strategies and clinical adoption pathways

Significant transformative shifts are reshaping how healthcare systems, clinicians, and manufacturers approach catheter-related bloodstream infections. Advances in material science and surface engineering are translating into new device-level protections, while incremental improvements in insertion technique, maintenance protocols, and real-time monitoring are altering clinical workflows. Together, these changes are creating a more layered defense against infection that extends beyond a single product or practice and toward integrated bundles of care.

Simultaneously, the role of evidence generation has intensified; high-quality comparative effectiveness research and pragmatic trials are influencing purchasing decisions and clinical guidelines, driving a movement from anecdote-driven adoption to data-driven implementation. Health systems are increasingly focused on measurable outcomes, which has elevated the importance of robust post-market surveillance and adoption of standardized infection tracking mechanisms. In parallel, digital health tools-ranging from electronic checklists to remote monitoring of catheter dwell times-are being piloted and, in some cases, scaled to support adherence and early detection of complications.

Moreover, cross-sector collaboration is becoming more prominent: manufacturers are partnering with clinicians and academic centers to co-develop protocols that optimize device use in real-world settings, and payers are engaging in value-based conversations that prioritize durable clinical benefit. Taken together, these transformative shifts are producing a dynamic environment where incremental technical advances, rigorous evidence, and system-level incentives coalesce to change both practice and procurement in infection prevention.

Assessing how tariff-driven shifts in sourcing, pricing, and supplier strategy are reshaping procurement decisions and supply chain resilience for infection prevention products

Recent tariff changes in the United States have introduced a new variable into supply chain calculus and procurement decision-making for catheter-related infection prevention products. The cumulative impact extends beyond simple price adjustments and touches vendor sourcing strategies, inventory management, and the competitive dynamics between domestic manufacturers and foreign suppliers. Procurement teams have been required to reassess supplier diversity, dual sourcing, and inventory buffers to mitigate the risk of downstream shortages or cost volatility.

Manufacturers facing higher input costs and potential import levies have responded with a mix of nearshoring, renegotiation with component vendors, and targeted price realignments. These responses, in turn, influence hospital purchasing behavior, encouraging longer-term contracting, increased emphasis on total cost of ownership, and more rigorous supplier performance metrics. In some cases, health systems are accelerating adoption of products with proven efficacy that can reduce length of stay or complication-related resource use, thereby offsetting incremental acquisition costs.

Regulatory and policy stakeholders have also adapted by issuing guidance to ensure continuity of care and to prioritize supply chain transparency. Meanwhile, industry participants are exploring collaborative procurement consortia and pooled purchasing arrangements to preserve purchasing leverage and normalize access across different facility types. The net effect is a market that is more attuned to supply chain resilience and value-driven procurement, with organizations balancing cost pressures against the clinical imperative to prevent avoidable bloodstream infections.

Deep segmentation insights revealing how device type, care setting, and coating technologies intersect to shape clinical selection, procurement, and implementation strategies

Segment-level analysis reveals distinct dynamics across product type, end user, and coating modality that collectively inform adoption and innovation priorities. Based on product type, the landscape differentiates between central venous catheters and peripheral venous catheters, with central venous catheters further divided into non-peripherally inserted central catheters and peripherally inserted central catheters, while peripheral venous catheters encompass midline catheters and standard peripheral intravenous catheters; each subcategory presents unique clinical indications, dwell time considerations, and risk profiles that influence device selection and adjunctive prevention strategies.

Based on end user, utilization and purchasing pathways vary across ambulatory surgical centers, home care settings, and hospitals, with each setting imposing distinct logistic, staffing, and training constraints. Hospitals typically centralize infection control expertise and have established procurement infrastructures, whereas ambulatory surgical centers and home care settings may prioritize devices that are simple to use, require minimal maintenance, and support rapid patient turnover or remote management.

Based on coating, differentiation between antimicrobial coated and non-coated devices is a critical axis. The antimicrobial coated segment is further characterized by antibiotic-impregnated, chlorhexidine coated, and silver coated options, each offering different spectra of antimicrobial activity, longevity, and regulatory considerations. These coating choices interact with clinical protocols and stewardship priorities, influencing clinician preference, formulary decisions, and post-market surveillance requirements. Understanding how these segmentation dimensions intersect is essential for stakeholders aiming to optimize clinical outcomes while aligning with operational needs and stewardship goals.

How regional regulatory frameworks, manufacturing footprints, and clinical practice variability across key geographies drive differentiated strategies for device adoption and distribution

Regional dynamics influence clinical practice, regulatory emphasis, and supply chain architecture in ways that matter to stakeholders operating across Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, policy emphasis on quality metrics and reimbursement-linked outcomes has pushed institutions to prioritize interventions with demonstrable reductions in infection risk, while robust domestic manufacturing capacity has supported supply chain continuity in many areas. In contrast, Europe, Middle East & Africa present a more heterogeneous environment where regulatory frameworks, health infrastructure maturity, and procurement models vary significantly, driving the need for region-specific strategies and localized evidence to support product adoption.

Asia-Pacific is characterized by rapid infrastructure expansion, growing clinical capacity in both acute and community care, and an increasing focus on infection prevention as standards evolve. Supply chain dynamics across these regions differ as well, with Asia-Pacific often serving as a key manufacturing hub and the Americas and Europe representing large, sophisticated demand centers. These regional contrasts create opportunities for tailored go-to-market approaches that account for regulatory pathways, local clinical practice patterns, and distribution network realities.

Consequently, companies and health systems should calibrate their regional engagement strategies to reflect differences in evidence requirements, procurement cycles, and implementation capacity. Regional partnerships, targeted clinical data generation, and adaptive distribution models are typically most effective when they align with the specific operational and regulatory contours of each geography.

Competitive and collaborative strategies among manufacturers and service providers that prioritize evidence generation, integrated solutions, and supply chain resilience to gain clinical trust

Competitive activity among device manufacturers, coating technology providers, and services organizations is shaping both product development and market engagement strategies. Leading players are investing in next-generation materials and coating chemistries that improve antimicrobial performance while minimizing impact on antimicrobial stewardship initiatives. At the same time, portfolio diversification is evident as manufacturers seek to offer bundled solutions that combine devices, training, and digital adherence tools to strengthen clinical outcomes and customer retention.

Strategic partnerships between industry and clinical centers of excellence are increasingly common, facilitating real-world evidence generation and supporting guideline inclusion. Meanwhile, contract manufacturers and logistics providers are evolving their service offerings to address resilience concerns by providing dual-sourcing options, localized inventory hubs, and enhanced traceability. Mergers and acquisitions activity continues to reflect a desire to integrate novel coating technologies and point-of-care monitoring capabilities into broader product suites, enabling companies to offer differentiated value propositions to hospitals and alternative care sites.

Innovation in post-market surveillance and data analytics is also influencing competitive positioning, as companies that can demonstrate longitudinal safety and efficacy data gain traction with procurement committees and clinical leaders. Overall, the competitive landscape prizes agility in R&D, capacity to generate strong clinical evidence, and the ability to deliver comprehensive solutions that reduce infection risk across diverse care settings.

Practical, evidence-driven actions for manufacturers and health systems to enhance clinical outcomes, secure supply chain continuity, and accelerate safe adoption of infection prevention innovations

Industry leaders should adopt a pragmatic, multi-dimensional strategy to reduce catheter-related bloodstream infections that balances innovation, implementation, and system-level change. First, prioritize investment in clinical evidence that demonstrates not just product performance but real-world impact on infection rates and resource utilization. Complement device innovation with prospective observational studies and partnerships with health systems to capture meaningful outcomes and implementation insights.

Second, strengthen supply chain resilience through supplier diversification, contingency inventory strategies, and collaborative procurement models. Near-term tariff and trade uncertainties underscore the value of local manufacturing options and flexible sourcing arrangements, which can reduce exposure to single-source disruptions and support steady access to critical components and finished devices.

Third, integrate product adoption with workforce training and process redesign. Devices with advanced coatings or novel designs should be introduced alongside comprehensive competency programs, standardized insertion and maintenance bundles, and digital tools that support adherence and monitoring. Embedding change management and clear accountability in clinical pathways increases the likelihood that technical benefits translate into measurable reductions in infection risk.

Finally, engage proactively with regulators and payers to align on evidence requirements and reimbursement models that recognize the longer-term value of infection prevention. By taking a holistic approach that combines robust evidence, operational readiness, and adaptive procurement, leaders can accelerate safe adoption while managing cost and compliance pressures.

A transparent mixed-methods approach combining clinician interviews, guideline review, and triangulated evidence synthesis to produce rigorous and actionable insights

The research methodology underpinning this analysis leverages a blend of primary and secondary approaches to ensure rigor, triangulation, and relevance to stakeholders. Primary research comprised structured interviews with clinicians, infection prevention specialists, procurement leaders, and industry executives to capture first-hand perspectives on device performance, adoption barriers, and operational priorities. These interviews were complemented by targeted consultations with regulatory experts and supply chain managers to understand policy implications and logistics considerations.

Secondary research involved systematic review of peer-reviewed literature, clinical guidelines, and regulatory documents to contextualize primary findings within the broader evidence landscape. Where available, post-market surveillance reports, real-world evidence studies, and technical white papers were reviewed to assess safety and performance claims. Data synthesis prioritized cross-validation across sources to reconcile discrepancies and highlight consensus areas versus topics requiring further investigation.

Analytical techniques included qualitative thematic analysis to extract recurrent themes and drivers, as well as comparative assessment frameworks to evaluate relative strengths and limitations across device types, coatings, and care settings. Limitations of the methodology are acknowledged, including variability in published data granularity across regions and rapid innovation cycles that may alter the evidence base over short horizons. To mitigate these constraints, the study incorporated stakeholder validation and iterative review cycles to ensure findings remain robust and actionable.

A strategic synthesis underscoring the imperative of combining innovation, evidence, and operational rigor to consistently reduce infection risk and improve patient safety

In conclusion, addressing catheter-related bloodstream infections requires an integrated strategy that aligns device innovation, clinical practice improvement, and supply chain robustness. Technical advances in catheter design and antimicrobial coatings are important, but their full value is realized only when paired with rigorous evidence generation, comprehensive training, and operational systems that support adherence. As stakeholders navigate tariff-driven disruptions and regional variability, a focus on resilience, targeted data, and collaborative implementation will distinguish effective programs from those that fall short.

Leaders should therefore pursue coordinated investments: prioritize evidence that demonstrates clinical and operational benefit, build procurement strategies that minimize disruption risk, and embed change management into clinical rollouts. By doing so, health systems can protect patient safety while preserving financial sustainability, and manufacturers can create durable partnerships with customers grounded in measurable outcomes. The path forward emphasizes iterative learning, cross-sector collaboration, and a sustained commitment to translating technical promise into consistent, real-world reductions in infection risk.

These conclusions offer a strategic foundation for stakeholders ready to move from analysis to action, and the recommendations herein are intended to inform both near-term tactical decisions and longer-range strategic planning in the pursuit of safer vascular access care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Catheter-related Bloodstream Infections Market, by Product Type

  • 8.1. Central Venous Catheters
    • 8.1.1. Non-Peripherally Inserted Central Catheters
    • 8.1.2. Peripherally Inserted Central Catheters
  • 8.2. Peripheral Venous Catheters
    • 8.2.1. Midline Catheters
    • 8.2.2. Standard Peripheral Intravenous Catheters

9. Catheter-related Bloodstream Infections Market, by Coating

  • 9.1. Antimicrobial Coated
    • 9.1.1. Antibiotic Impregnated
    • 9.1.2. Chlorhexidine Coated
    • 9.1.3. Silver Coated
  • 9.2. Non-Coated

10. Catheter-related Bloodstream Infections Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Care Settings
  • 10.3. Hospitals

11. Catheter-related Bloodstream Infections Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Catheter-related Bloodstream Infections Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Catheter-related Bloodstream Infections Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Catheter-related Bloodstream Infections Market

15. China Catheter-related Bloodstream Infections Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Advacare Pharma
  • 16.6. AstraZeneca PLC
  • 16.7. Bactiguard AB
  • 16.8. Becton, Dickinson and Company
  • 16.9. CorMedix Inc
  • 16.10. Fresenius Medical Care AG
  • 16.11. Glenmark Pharmaceuticals Ltd.
  • 16.12. IntegraDose Compounding Services, LLC
  • 16.13. Johnson & Johnson Services, Inc
  • 16.14. JoinHub Pharma
  • 16.15. Lupin Ltd.
  • 16.16. Lyka Hetero Healthcare Ltd.
  • 16.17. Merck & Co., Inc.
  • 16.18. Novartis AG
  • 16.19. Pfizer Inc.
  • 16.20. Sanofi SA
  • 16.21. TauroPhar GmbH
  • 16.22. Xellia Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-PERIPHERALLY INSERTED CENTRAL CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERALLY INSERTED CENTRAL CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY MIDLINE CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STANDARD PERIPHERAL INTRAVENOUS CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIBIOTIC IMPREGNATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CHLORHEXIDINE COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SILVER COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY NON-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 120. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 121. GCC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 141. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 142. G7 CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 146. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 147. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 148. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 149. NATO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CENTRAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY PERIPHERAL VENOUS CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COATING, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ANTIMICROBIAL COATED, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)